Johnson & Johnson $JNJ Shares Purchased by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 151,082 shares of the company’s stock after acquiring an additional 18,507 shares during the period. Johnson & Johnson comprises about 0.5% of Bridgeway Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. Bridgeway Capital Management LLC’s holdings in Johnson & Johnson were worth $23,078,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. GFG Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $48,000. Vermillion & White Wealth Management Group LLC increased its stake in shares of Johnson & Johnson by 66.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after buying an additional 150 shares during the last quarter. Gladwyn Financial Advisors Inc. acquired a new stake in Johnson & Johnson in the second quarter valued at $71,000. Finally, Pandora Wealth Inc. raised its holdings in Johnson & Johnson by 22.1% in the second quarter. Pandora Wealth Inc. now owns 476 shares of the company’s stock valued at $73,000 after acquiring an additional 86 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.8%

NYSE:JNJ opened at $211.65 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average of $196.09 and a 200-day moving average of $177.08. The firm has a market capitalization of $509.93 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $212.27.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Argus set a $210.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. UBS Group increased their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. Finally, Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $206.65.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.